10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
暂无分享,去创建一个
David Gillatt | Richard M Martin | John Staffurth | Edward Rowe | Chris Metcalfe | Freddie C Hamdy | Roger Kockelbergh | Peter Holding | Jon Oxley | Jenny L Donovan | Stephen Prescott | Andrew Doble | Tim J Peters | J Athene Lane | David E Neal | T. Peters | J. Oxley | F. Hamdy | D. Neal | J. Donovan | D. Gillatt | M. Mason | J. Staffurth | J. Catto | C. Metcalfe | Richard M. Martin | J. Lane | P. Holding | Michael Davis | E. Turner | M. Robinson | E. Walsh | P. Bollina | A. Doble | A. Doherty | R. Kockelbergh | H. Kynaston | A. Paul | P. Powell | S. Prescott | D. Rosario | E. Rowe | Michael Davis | Emma L Turner | Eleanor Walsh | Derek J Rosario | James Catto | Howard Kynaston | Malcolm Mason | Mary Robinson | Prasad Bollina | Alan Doherty | Alan Paul | Philip Powell | Tim J. Peters | M. Davis | David E. Neal | T. Peters | Mary Robinson
[1] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[2] P Bauer,et al. Multiple testing in clinical trials. , 1991, Statistics in medicine.
[3] Hans Garmo,et al. Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.
[4] A. Partin,et al. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? , 2008, Urology.
[5] D. Dearnaley,et al. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397). , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[7] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[8] F. Hamdy,et al. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[9] F. Hamdy,et al. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) , 2015, BMC Medical Research Methodology.
[10] P. Walsh. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.
[11] Monique J. Roobol,et al. Mortality Results from a Randomized ProstateCancer Screening Trial , 2009 .
[12] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[13] L. Holmberg,et al. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. , 2015, European urology.
[14] J. Sterne,et al. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) , 2014, British Journal of Cancer.
[15] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[16] Mufaddal Mamawala,et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Peters,et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. , 2014, The Lancet. Oncology.
[18] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[19] M. Sydes,et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] Anssi Auvinen,et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.
[21] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[22] J. Oxley,et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee , 2016, British Journal of Cancer.
[23] C. Lawton,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .
[24] A. D'Amico. Treatment or Monitoring for Early Prostate Cancer. , 2016, The New England journal of medicine.
[25] Peter Kirkbride,et al. Prostate cancer: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.
[26] A. Auvinen,et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. , 2015, Journal of the National Cancer Institute.
[27] B. G. Blijenberg,et al. Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.
[28] David Gillatt,et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.
[29] J. Gohagan,et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.
[30] M. Roobol,et al. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. , 2015, European urology.
[31] Jonathan E. Shoag,et al. Reevaluating PSA Testing Rates in the PLCO Trial. , 2016, The New England journal of medicine.
[32] R. Volk,et al. Grading the new US Preventive Services Task Force prostate cancer screening recommendation. , 2011, JAMA.
[33] Joyce E. Wilkinson,et al. Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life , 2016, BJU international.
[34] Ronald C. Chen,et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Taneja,et al. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. , 2015, The Journal of urology.
[36] Paul W Dickman,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[37] Danny Vesprini,et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.